Abstracts tagged "Tumor necrosis factor (TNF)"

Abstract Number: 0016 • ACR Convergence 2023
Role of TP53 in Inflammatory Reprogramming of Rheumatoid Arthritis Synovial Fibroblasts
Anil Singh and Salahuddin Ahmed, Washington State university, Spokane, WA
Background/Purpose: TP53, a tumor-suppressor protein known as the guardian of the genome, plays a critical role in regulating genomic stability and cellular function. When TP53…
Abstract Number: 1673 • ACR Convergence 2023
Immunomodulatory Treatment and Autoimmune Patient Responses to COVID-19 Booster Shots: Results from the Covid-19 VaccinE Response in Rheumatology Patients (COVER) Study
Amy S. Mudano¹, Gary Cutter², Ted R Mikuls³, Geoffrey Thiele⁴, Emily Holladay², Kevin Withrop⁵, Mark Law⁴, Bart Hamilton⁴, Monique Bastidas⁶, Michael Zikry⁶, Kelly Chun⁶, Michael George⁷ and Jeffrey Curtis², ¹Illumination Health, Hoover, AL, ²University of Alabama at Birmingham, Birmingham, AL, ³Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE, ⁴University of Nebraska Medical Center, Omaha, NE, ⁵Oregon Health & Science University, Schools of Medicine and Public Health,, Portland, OR, ⁶Labcorp, Calabasas, CA, ⁷University of Pennsylvania, Philadelphia, PA
Background/Purpose: Given an increased risk of COVID-19 in patients with autoimmune conditions, we must better understand the immunogenicity and safety of SARS-CoV-2 vaccines in people…
Abstract Number: 0370 • ACR Convergence 2023
Clinical Disease Manifestations Associated with TNF Inhibitor Non-Response in Juvenile Spondyloarthritis
Melissa Oliver¹, Kelly Mosesso², Pamela F. Weiss³, Robert Colbert⁴, Matthew Stoll⁵ and Hemalatha Srinivasalu⁶, ¹Indiana University, Indianapolis, IN, ²Indiana University School of Medicine, Indianapolis, IN, ³Children's Hospital of Philadelphia, Philadelphia, PA, ⁴NIH/NIAMS, Bethesda, MD, ⁵University of Alabama at Birmingham, Birmingham, AL, ⁶Children's National Hospital, Washington, DC
Background/Purpose: Tumor necrosis factor inhibitors (TNFi) are effective in children with juvenile spondyloarthritis (JSpA) and generally represent the first-line choice for biologic therapy. However, not…
Abstract Number: 1725 • ACR Convergence 2023
Distinct Perivascular and Intravascular Lymphatic Mast Cells and Their Role in Lymphatic Clearance, Joint Inflammation, and Bone Erosion in the TNF-Transgenic Murine Arthritis Model
Yue Peng¹, H. Mark Kenney², Karen Bentley³, Lianping Xing⁴, Christopher T Ritchlin⁵ and Edward Schwarz³, ¹University of Rochester Medical Center, Rochester, NY, ²University of Rochester School of Medicine and Dentistry, Henrietta, NY, ³University of Rochester, Rochester, NY, ⁴University of Rochester Medical Center, Webster, NY, ⁵University of Rochester Medical School, Allergy, Immunology & Rheumatology Division, Canandaigua, NY
Background/Purpose: Inflammatory-erosive arthritis is exacerbated by lymphatic dysfunction (1), and mast cells (MCs) regulate lymphatic vessel contractions via release of inflammatory and vasoactive mediators (2).…
Abstract Number: 0404 • ACR Convergence 2023
Persistent Pain and Its Predictors After Start of Anti-TNF Therapy in Rheumatoid Arthritis – Is Line of Treatment Linked to Different Pain Patterns?
Carmen Roseman, Johan Karlsson Wallman, Jon Einarsson, Elisabeth Mogard, Elisabet Lindqvist, Meliha Kapetanovic and Tor Olofsson, Lund University and Skåne University Hospital, Lund, Sweden
Background/Purpose: Persisting pain with or without inflammation control is a common and debilitating symptom in rheumatoid arthritis (RA). Concerns have been raised that patients with…
Abstract Number: 1767 • ACR Convergence 2023
TNF-α Utilizes the TWEAK/Fn-14 Axis in Human Rheumatoid Arthritis Synovial Fibroblasts to Induce Inflammation
Farheen Sultan Shaikh¹, Anil Singh¹, Paul Panipinto² and Salahuddin Ahmed¹, ¹Washington State University, Spokane, WA, ²Washington State University College of Pharmaceutical Science and Molecular Medicine, Spokane, WA
Background/Purpose: Tumor necrosis factor-alpha (TNF)-α is a proinflammatory cytokine in rheumatoid arthritis that transduces intracellular signal transduction pathways through specific receptors, TNF-R1, and TNF-R2. The…
Abstract Number: 0429 • ACR Convergence 2023
Direct and Indirect Effects of Upadacitinib or Adalimumab on Pain in Rheumatoid Arthritis: Results from a Randomized Phase 3 Study
Peter C. Taylor¹, David Walsh², Tsutomu Takeuchi³, Bruno Fautrel⁴, Janet Pope⁵, Andrew Garrison⁶, Yanna Song⁶, Sara K. Penn⁶, Ralph Lippe⁷, Diane Caballero⁸ and Arthur Kavanaugh⁹, ¹Nuffield Department of Orthopedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ²University of Nottingham, Nottingham, United Kingdom, ³Keio University School of Medicine and Saitama Medical University, Tokyo, Japan, ⁴Sorbonne Université APHP, Paris, France, ⁵University of Western Ontario, London, ON, Canada, ⁶AbbVie, Inc., North Chicago, IL, ⁷AbbVie Deutschland GmbH & Co. KG, Wiesbaden, Germany, ⁸AbbVie, Inc., Chicago, IL, ⁹University of California San Diego, School of Medicine, Riverside, CA
Background/Purpose: Rapid and sustained pain control is an important goal for patients (pts) with rheumatoid arthritis (RA). Control of inflammation in RA does not always…
Abstract Number: 2019 • ACR Convergence 2023
2023 EULAR Recommendations for the Management of Fatigue in People with Inflammatory Rheumatic and Musculoskeletal Diseases
Emma Dures¹, Bayram Farisogullari², Eduardo Santos³, Anna Molto⁴, Caroline Feldthusen⁵, Claire Harris⁶, Corinna Elling-Audersch⁷, Deirdre Conolly⁸, Elena Elefante⁹, Fernando Estévez-López¹⁰, Ilaria Bini¹¹, Jette Primdahl¹², Kirsten Hoeper¹³, Marie Urban¹⁴, Mart van de Laar¹⁵, Marta Redondo¹⁶, Peter Böhm¹⁷, Raj Amarnani¹⁸, Rhys Hayward⁶, Rinie Geenen¹⁹, Simona Rednic²⁰, Susanne Pettersson²¹, Tanja Thomsen²², Till Uhlig²³, Valentin Ritschl²⁴ and Pedro Machado²⁵, ¹Academic Rheumatology, Bristol Royal Infirmary; and Faculty of Health and Applied Sciences, University of the West of England, Bristol, United Kingdom, ²Hacettepe University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey, ³Health Sciences Research Unit: Nursing (UICISA: E), Nursing School of Coimbra (ESEnfC), Coimbra, Portugal, ⁴HOPITAL COCHIN AP-HP, Service de Rhumatologie, Paris, France, ⁵Institute of Neuroscience and Physiology, University of Gothenburg, Department of Health and Rehabilitation, Unit of Physiotherapy, Sahlgrenska Academy, Gothenburg, Sweden, ⁶Northwick Park Hospital, London North West University Healthcare NHS Trust, Department of Rheumatology, London, United Kingdom, ⁷Deutsche Rheuma-Liga Bundesverband e.V., Patient Research Partner, Bonn, Germany, ⁸School of Medicine, Trinity College Dublin, Discipline of Occupational Therapy, Dublin, Ireland, ⁹Rheumatology Unit, Department of clinical and experimental medicine, University of Pisa, Pisa, Italy, ¹⁰Harvard T.H. Chan School of Public Health, Department of Social and Behavioral Sciences, Boston, MA, ¹¹Anmar, Young, Rome, Italy, Rome, Italy, ¹²University Hospital of Southern Denmark, Danish Hospital for Rheumatic Diseases, Sønderborg, Denmark, ¹³Hannover Medical School, Department of Rheumatology and Immunology, Hannover, Germany, ¹⁴University Hospitals Bristol, Research Design Service, Bristol, United Kingdom, ¹⁵University of Twente, Department of Psychology, Health and Technology, Enschede, Netherlands, ¹⁶Camilo José Cela University, Faculty of Heath Sciences, Madrid, Spain, ¹⁷German League against rheumatism, Forschungspartner, Bonn, Germany, ¹⁸Barts Health NHS Trust, Barts Health Rheumatology Service, London, United Kingdom, ¹⁹Utrecht University, Vorstenbosch, Netherlands, ²⁰Prof Dr Simona Rednic, Cluj, Romania, ²¹Karolinska Institute, Division of Rheumatology, Department of Medicine Solna, Stockholm, Sweden, ²²University of Copenhagen, Copenhagen Centre for Arthritis Research, Centre for Rheumatology and Spine Diseases VRR, Rigshospitalet, Copenhagen, Denmark, ²³Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, ²⁴Medical University of Vienna, Vienna, Austria, ²⁵Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, UK. Department of Rheumatology, Northwick Park Hospital, London North West University Healthcare NHS trust, London, UK., London, United Kingdom
Background/Purpose: Fatigue is prevalent in people with inflammatory rheumatic and musculoskeletal diseases (I-RMDs) and recognized as one of the most challenging symptoms to manage (1).…
Abstract Number: 0443 • ACR Convergence 2023
The Potential of an Oral TNFα Inhibitor with TNFR1 Specificity: Results of a Phase 1b Proof-of-mechanism Trial in Psoriasis
Anna Fishbein¹, Mai Anh Nguyen², Ohn Chow³, Tiago Matos⁴, Caroline Dreis⁵, Hong Zhang³, Marion Poirel⁶, Johann Gassenhuber⁵, Michael Dufault³, Wagner Frank-Dietrich⁷, Laurent Perrin⁸, Markus Rehberg⁵, Markus Kohlmann⁵ and Nassr Nassr⁵, ¹Sanofi, Bridgewater, NJ, ²Sanofi, Berlin, Germany, ³Sanofi, Cambridge, MA, ⁴Sanofi, Amsterdam, Netherlands, ⁵Sanofi, Frankfurt, Germany, ⁶IT&M Stats, Neuilly-sur-Seine, France, ⁷Charité Research Organisation, Berlin, Germany, ⁸Sanofi, Montpellier, France
Background/Purpose: TNFα inhibition is a cornerstone of therapy for rheumatologic disease, yet there is no orally administered TNFα inhibitor available. A novel oral TNFα inhibitor…
Abstract Number: 2142 • ACR Convergence 2023
Adherence Patterns in Rheumatoid Arthritis Patients Receiving a Janus Kinase (JAK) Inhibitor or a Tumor Necrosis Factor α Inhibitor (TNFi) After the Addition of a Black Box Warning to JAK Inhibitors
W. Cliff Rutter, Kunal Patel, Samantha Delgado, Guy Cozzi, Elisea Avalos-Reyes, Will Cavers, Chen Liu, Rashmi Grover, Lucia Feczko and Kjel Johnson, CVS Health, Woonsocket, RI
Background/Purpose: In 2021, the FDA concluded that there is an increased risk of serious heart-related events with the Janus Kinase (JAK) inhibitor tofacitinib, which is…
Abstract Number: 0525 • ACR Convergence 2023
Bimekizumab Achieved Sustained Improvements in Efficacy Outcomes in Patients with Axial Spondyloarthritis, Regardless of Prior TNF Inhibitor Treatment: Week 52 Pooled Results from Two Phase 3 Studies
Marina Nighat Magrey¹, Marleen van de Sande², Maxime Breban³, Filip Van den Bosch⁴, Carmen Fleurinck⁵, Ute Massow⁶, Natasha De Peyrecave⁷, Thomas Vaux⁸, Xenofon Baraliakos⁹ and Helena Marzo-Ortega¹⁰, ¹Case Western Reserve University, University Hospitals, Cleveland, OH, ²Amsterdam UMC, University of Amsterdam, Department of Rheumatology & Clinical Immunology and Department of Experimental Immunology, Amsterdam Infection & Immunity Institute; Amsterdam Rheumatology & Immunology Center (ARC), Academic Medical Center, Amsterdam, Netherlands, ³CHU Ambroise-Paré, Boulogne-Billancourt, Paris, France, ⁴Department of Internal Medicine and Pediatrics, Ghent University and VIB Center for Inflammation Research, Ghent, Belgium, ⁵UCB Pharma, Oosterzele, Belgium, ⁶UCB Pharma, Monheim am Rhein, Germany, ⁷UCB Pharma, Brussels, Belgium, ⁸UCB Pharma, Slough, United Kingdom, ⁹Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ¹⁰NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom
Background/Purpose: In patients (pts) with axial spondyloarthritis (axSpA), tumor necrosis factor inhibitors (TNFi) are the usual first line biologic treatment, yet many pts may experience…
Abstract Number: 2507 • ACR Convergence 2023
ZCCHC6 Modulates the Global Phosphorylation Landscape in TNF-a-induced Rheumatoid Arthritis Synovial Fibroblasts
Anil Singh, Farheen Sultan Shaikh and Salahuddin Ahmed, Washington State university, Spokane, WA
Background/Purpose: ZCCHC6, also known as TUT7 or TENT2, plays a crucial role in RNA processing and metabolism through its uridylyl transferase function. This function involves…
Abstract Number: 0542 • ACR Convergence 2023
Two-Year Treatment Adherence and Clinical Response to Secukinumab Compared to TNF Inhibitors in Axial and Peripheral Spondyloarthritis Patients: A Single-Center Prospective Observational Study
Irini Flouri¹, Argyro Repa², Nestor Avgoustidis², Sofia Pitsigavdaki³, Katerina Pateromichelaki², Maria Terizaki², George Bertsias⁴ and Prodromos Sidiropoulos⁴, ¹University of Crete Medical School, Heraklion, Greece, ²Rheumatology, Clinical Immunology and Allergy Department, Medical School, University of Crete, Heraklion, Greece, ³Rheumatology, Clinical Immunology and Allergy Department, Medical School, University of Crete, Crete, Greece, ⁴Rheumatology, Clinical Immunology and Allergy Department, Medical School, University of Crete, Greece; Institute of Molecular Biology and Biotechnology, Foundation for Research and Technology Hellas (FORTH), Heraklion, Greece
Background/Purpose: Anti-IL17 agent secukinumab (SEC) has been proven effective and is widely used in the treatment of spondyloarthritis (SpA) patients alternatively to tumor necrosis factor…
Abstract Number: 2541 • ACR Convergence 2023
Differential Responses to Initial Treatment Strategies for Rheumatoid Arthritis Among Those with Lower Body Mass and Adiposity
Joshua Baker¹, James O'Dell², Bryant England², Jon Giles³, Jefferey Newcomb⁴, Michael George¹, Geoffrey Thiele², Larry Moreland⁵, S. Louis Bridges⁶, Jeffrey R Curtis⁷ and Ted R Mikuls⁸, ¹University of Pennsylvania, Philadelphia, PA, ²University of Nebraska Medical Center, Omaha, NE, ³Columbia University, New York, NY, ⁴University of Nebraska, Omaha, NE, ⁵University of Colorado, Denver, CO, ⁶Hospital for Special Surgery, New York, NY, ⁷Division of Clinical Immunology and Rheumatology, University of Alabama, Birmingham, AL, ⁸Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: The identification of measures that help predict who is likely to benefit most from early escalation to biologic therapy would inform personalized care among…
Abstract Number: 0834 • ACR Convergence 2023
Characterization of the Youngest Cohort with Non-Systemic Juvenile Idiopathic Arthritis: Demographics and Medication Use of Patients ≤2 Years of Age in the Childhood Arthritis and Rheumatology Research Alliance Registry
Christina Gulla¹, Tara Lozy², Daniel Choi³, Ginger Janow⁴ and For The CARRA Registry Investgators⁵, ¹HUMC pediatrics residency, Hackensack, NJ, ²Ccenter for Discovery and Innovation, Hackensack, NJ, ³Hackensack Meridian School of Medicine, Nutley, NJ, ⁴Joseph M. Sanzari Children's Hospital at Hackensack Meridian Health, Glen Rock, NJ, ⁵CARRA, Inc, Washington, DC
Background/Purpose: Juvenile idiopathic arthritis (JIA) is the most common rheumatic disease in children. Tumor necrosis factor inhibitors (TNFi) have demonstrated efficacy and safety in older…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].